Please assess the completion status of the following clinical trial:

Trial Title: Exenatide Once Weekly for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be English-speaking volunteers who desire to quit smoking and are willing to make a quit attempt during the course of the study;~* Have smoked ≥10 cigarettes a day for at least one year and provide a breath carbon monoxide (CO) ≥10 ppm;~* Have a negative pregnancy test, if female of childbearing potential;~* Have HbA1C levels between 5.7 and 6.4% or BMI of or greater than 25 kg/square meters~* Not currently using any therapy for glycemic control (either injectable \[i.e. insulin\] or oral agents);~* Have vital signs as follows: resting pulse between 50 and 95 bpm, BP between 90-150 mmHg systolic and 45-95 mmHg diastolic;~* Have hematology and chemistry laboratory tests that are within reference limits (within 10% above or below), with the following exception: pancreatic tests (lipase and amylase) must be within normal limits;~* Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the principal investigator.~Exclusion Criteria:~* Meet criteria for the following psychiatric and/or substance use disorders as assessed by the Mini International Neuropsychiatric Interview (MINI): items C (current manic or hypomanic episode only), I (alcohol abuse - Alcohol Addendum-past 3 months only; current alcohol dependence), J (substance abuse -Substance Abuse Addendum - past 3 months only; current substance dependence), K (current psychotic disorder or current mood disorder with psychotic features).~* Individuals who meet criteria for non-exclusionary psychiatric disorders that are considered clinically unstable and/or unsuitable to participate as determined by the Principal Investigator and/or Study Physician.~* Individuals rated as moderate (9-16) to high (17 or greater) on suicidality as assessed by Module B of the MINI.~* Have personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2;~* Have type 1 diabetes mellitus;~* Have severe cardiovascular disease (history of myocardial infarction, life-threatening arrhythmia, or worsening angina pectoris);~* Have active temporomandibular joint disease;~* Have severe gastrointestinal disease (i.e. severe gastroparesis);~* Have previous history of pancreatitis or are at risk for pancreatitis;~* Have creatinine clearance (CrCl) \< 30;~* Have any previous medically adverse reaction to study medications, nicotine, or menthol;~* Be pregnant or lactating or unwilling to provide a negative pregnancy test before study entry;~* Not using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide);~* Have any illness which in the opinion of the primary investigator would preclude safe and/or successful completion of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide plus NRT plus counseling (Type: EXPERIMENTAL): Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
- Placebo plus NRT plus counseling (Type: PLACEBO_COMPARATOR): Once weekly placebo, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete